4
Changes in Ownership
Dianthus Therapeutics, Inc. /DE/ Filed Acc 0001778623-26-000007
SVP, General Counsel and Sec. sold 20,000 shares at an average $110.44 ($2,208,833)
- SVP, General Counsel and Sec. acquired 20,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Veness Adam M SVP, General Counsel and Sec. | 2026-08-07 | Option exercise 10b5-1 | +3,833 | $17.88 | $68,534 | 3,833 | D |
| Veness Adam M SVP, General Counsel and Sec. | 2026-08-07 | Sale 10b5-1 | −3,217 | $110.61 | $355,832 | 616 | D |
| Veness Adam M SVP, General Counsel and Sec. | 2026-08-07 | Sale 10b5-1 | −616 | $111.18 | $68,487 | 0 | D |
| Veness Adam M SVP, General Counsel and Sec. | 2026-08-10 | Option exercise 10b5-1 | +16,167 | $17.88 | $289,066 | 16,167 | D |
| Veness Adam M SVP, General Counsel and Sec. | 2026-08-10 | Sale 10b5-1 | −16,167 | $110.38 | $1,784,513 | 0 | D |
| Derivatives | |||||||
| Veness Adam M SVP, General Counsel and Sec. | 2026-08-07 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,833 | 76,167 | D | ||
| Veness Adam M SVP, General Counsel and Sec. | 2026-08-10 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −16,167 | 60,000 | D | ||
| Open-market sales · 20,000 sh · avg $110.44 · $2,208,833 | |||||||
Loading xslF345X06/ownership.xml…